FDA Draft Guidance Outlines ‘One-Trial’ Approval Process For Oncology Drugs

By Jessica Karins / March 27, 2023 at 7:59 PM
FDA signals in a new draft guidance that using the same clinical trial population for both accelerated and full approval applications and relying on surrogate endpoints data for both steps could become more common. Although the draft applies only to oncology products, the same process has been used for other drugs, including the Alzheimer’s medication Leqembi (lecanemab), produced by Eisai, Inc. and Biogen; after receiving accelerated approval in January, the sponsors are seeking full approval based on later surrogate endpoints...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.